Cargando…
Acute Myeloid Leukemia in the Elderly Patient: New Strategies
Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. I...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837938/ https://www.ncbi.nlm.nih.gov/pubmed/27182475 http://dx.doi.org/10.1007/s40487-015-0006-7 |
_version_ | 1782427931030585344 |
---|---|
author | Thomas, Xavier |
author_facet | Thomas, Xavier |
author_sort | Thomas, Xavier |
collection | PubMed |
description | Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40487-015-0006-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4837938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-48379382016-05-11 Acute Myeloid Leukemia in the Elderly Patient: New Strategies Thomas, Xavier Rare Cancers Ther Review Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40487-015-0006-7) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-07-04 2015 /pmc/articles/PMC4837938/ /pubmed/27182475 http://dx.doi.org/10.1007/s40487-015-0006-7 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Thomas, Xavier Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title | Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title_full | Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title_fullStr | Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title_full_unstemmed | Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title_short | Acute Myeloid Leukemia in the Elderly Patient: New Strategies |
title_sort | acute myeloid leukemia in the elderly patient: new strategies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837938/ https://www.ncbi.nlm.nih.gov/pubmed/27182475 http://dx.doi.org/10.1007/s40487-015-0006-7 |
work_keys_str_mv | AT thomasxavier acutemyeloidleukemiaintheelderlypatientnewstrategies |